Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators

University of Calgary

$100,000.00

The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project

EF 2013-14

Résumé
Childhood nephrotic syndrome is a common childhood kidney disease. Children with nephrotic syndrome leak protein from blood into urine. Many of those affected can have a relapsing course of disease. Steroids are the treatment of choice for nephrotic syndrome and repeated treatment courses of steroid can lead to significant toxicity. In our previous work, we found wide variability in treatments used for childhood nephrotic syndrome in Canada, in particular the dose and duration of steroids prescribed. We also compared current management practices for nephrotic syndrome with recently published Clinical Practice Guideline that summarizes the best evidence for effective treatments of nephrotic syndrome. We found several gaps between what is published in the Guideline and what is done in practice. The extent of variation in steroid treatment protocols, factors driving this variation and impact of variation on patient outcomes are unknown. Therefore, there is a need to identify and understand factors influencing variability in treatment and to determine whether variability in treatment affects patient outcomes. Our work plan is as follows. First, we will study factors influencing total steroid exposure during the first presentation of nephrotic syndrome and subsequent relapses. Second, we will interview physicians and nurses who care for patients with nephrotic syndrome to understand reasons behind their choices in dosing and duration of steroid therapy. We will also determine the effect of the amount of steroids used to treat first presentation of nephrotic syndrome on the risk of getting a subsequent relapse. In summary, this study will help us understand the factors that influence treatment variability and will help us develop strategies to implement a standardized protocol to treat childhood nephrotic syndrome in the future. We will also use the results of this study to design clinical trials to study effectiveness of treatments for nephrotic syndrome.
Programme
Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
299978
Name
Samuel Susan M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant-PA: INMD Start Up Funds (bridge funding) - New Investigators
Keyworddelim
Children; Kidney; Knowledge Translation; Longitudinal Registry; Multi-Level Modeling; Nephrotic Syndrome; Practice Variation; Qualitative Methods
Abstract
Childhood nephrotic syndrome is a common childhood kidney disease. Children with nephrotic syndrome leak protein from blood into urine. Many of those affected can have a relapsing course of disease. Steroids are the treatment of choice for nephrotic syndrome and repeated treatment courses of steroid can lead to significant toxicity. In our previous work, we found wide variability in treatments used for childhood nephrotic syndrome in Canada, in particular the dose and duration of steroids prescribed. We also compared current management practices for nephrotic syndrome with recently published Clinical Practice Guideline that summarizes the best evidence for effective treatments of nephrotic syndrome. We found several gaps between what is published in the Guideline and what is done in practice. The extent of variation in steroid treatment protocols, factors driving this variation and impact of variation on patient outcomes are unknown. Therefore, there is a need to identify and understand factors influencing variability in treatment and to determine whether variability in treatment affects patient outcomes. Our work plan is as follows. First, we will study factors influencing total steroid exposure during the first presentation of nephrotic syndrome and subsequent relapses. Second, we will interview physicians and nurses who care for patients with nephrotic syndrome to understand reasons behind their choices in dosing and duration of steroid therapy. We will also determine the effect of the amount of steroids used to treat first presentation of nephrotic syndrome on the risk of getting a subsequent relapse. In summary, this study will help us understand the factors that influence treatment variability and will help us develop strategies to implement a standardized protocol to treat childhood nephrotic syndrome in the future. We will also use the results of this study to design clinical trials to study effectiveness of treatments for nephrotic syndrome.
Competitiondate
201309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Samuel, Susan M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~